[P32] Poster Session 32　Hematologic Malignancies 2

[P32-1] TP-3654, an oral PIM kinase inhibitor, in intermediate-2 or high-risk primary or secondary myelofibrosis: Phase 1 Study

^○Sujan Kabir¹, Golam Mohi², Jian Mei¹, Huyuan Yang¹, Carl Stapinski¹, Hongliang Cai¹, Jason M. Foulks¹, Steven L. Warner¹, Claudia Lebedinsky¹ (1.Sumitomo Dainippon Pharma Oncology, Inc., 2.University of Virginia School of Medicine)